Development of HeartLander as an epicardial injection delivery system

开发 HeartLander 作为心外膜注射输送系统

• 批准号: 8207011
• 负责人: Dwight Meglan
• 金额: $ 9.85万
• 依托单位: HEARTLANDER SURGICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-20 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8207011
• 关键词: Address; Basic Science; Cardiac; Catheters; Characteristics; Clinical; Development; Effectiveness; Endoscopy; Family suidae; Funding; Heart; Heart Valves; Heart failure; Injectable; Injection of therapeutic agent; Innovative Therapy; Location; Measures; Mechanics; Movement; Myocardial; Myocardium; Natural regeneration; Needles; Outcomes Research; Patients; Performance; Phase; Research; Safety; Specific qualifier value; Staging; Stem cells; Suction; Surface; System; Tissues; Translating; Trauma; United States National Institutes of Health; Walkers; Work; flexibility; foot; in vivo; meetings; minimally invasive; pericardial sac; prototype; research study

DESCRIPTION (provided by applicant): Numerous innovative therapies that must be delivered into the heart wall are now under development. These therapies typically require precise placement of a precise measure of an injectable substance and are intended to be delivered by minimally invasive means to minimize patient trauma. Unfortunately, traditional approaches for delivering such therapies, such as intracoronary and endocardial catheters and flexible endoscopy, have proven insufficient. The HeartLander epicardial delivery system has shown great potential for addressing this issue in its research outcomes to date. This proposed effort will take the HeartLander research prototype and translate it to be appropriate for meeting clinical needs by providing it with needed functional and safety capabilities. PUBLIC HEALTH RELEVANCE: By developing the HeartLander epicardial delivery system to have the needed clinical and safety characteristics to allow a host of innovative therapies to be reliably injected into the heart wall with minimal invasiveness to the patient, a spectrum of vexing cardiac conditions will be treatable that are now not well handled.

描述（由申请人提供）：目前正在开发许多必须输送到心脏壁的创新疗法。 这些疗法通常需要精确放置精确测量的可注射物质，并且旨在通过微创手段递送以最小化患者创伤。 不幸的是，传统的方法，如冠状动脉内和血管内导管和柔性内窥镜，已被证明是不够的。 HeartLander心外膜输送系统在迄今为止的研究成果中显示出解决这一问题的巨大潜力。 这项拟议的工作将采用HeartLander研究原型，并通过为其提供所需的功能和安全能力，将其转化为适合满足临床需求的产品。 公共卫生相关性：通过开发HeartLander心外膜输送系统，使其具有所需的临床和安全特性，以允许将大量创新疗法可靠地注入心脏壁，对患者的侵入性最小，一系列令人烦恼的心脏疾病将可以治疗，而这些疾病现在还没有得到很好的处理。